RMC No. 81-2021 — Publishes the letter from the Food and Drug Administration containing the “List of VAT-Exempt Products” pursuant to RA No. 11534 (CREATE Act) Digest | Full Text | FDA Endorsement Letter | List of VAT-Exempt Products

REPUBLIC OF THE PHILIPPINES DEPARTMENT OF FINANCE BUREAU OF INTERNAL REVENUE Quezon City lul 0 0 2021 REVENUE MEM,nAr\DUM .TRCULAR No. fi - fur&l SUBJECT : Publishing the futl text of the'letter from the F'oocl and Drug Administration (fDA) of the Departrnent of tflealth (BOH) containing the 'ol,ist of VAT-Exempt Products"- pursuant to Republic Act No. 11534 otherwise known as ttre Corporate Recovery and Tax Iincentives for Enterprises (CREATE) Act TO AII Internal Revenue Officers, Employees and Other Conc,erned For the intbrmation and guidance of all internal revenue oflicers, employees zrnd others concerned, attached is the letter dated June 17 , 2A21 from Rolando Enrique D. Dorningo, Director General of FDA, and the copy of the "List of VAT-Exempt Products'" consisting of fifty-eight (58) pages. The VAT exemption for the sale or importa,,ion of the fbllowing shall take effect on: a. Medicines for diabetes, high cholesterol, and hypertension beginningJanuarv \,2$20. b. Medicines for cancer, mental illness, tuberculosis, and kidney diseases !,eglllming Januarv tr. 2021; c. Drugs and vaccines prescribed and directly used trbr COVID-19 tre;itment b,e.ginning Januarv I.2021 until Decernlrer 31. 2023; and d. Medical devices directly used fbr COVID-i9 treatnrent beginrninE Jalrqari, X,.2021 until December 31 .2023. All internal revenue of-ficials and employees are hereby enjoined to give this Circuiar as wide a publicity as possible. ir.r?rn-runL REvENUE -/lt^$-4'-A:*=v CAESAR. R. DTILA,Y JUh'oi,ffi L' omrn is,s ioner of' Int ern ttl R evenue K-l r 043 3 o o 0M I t